NLS Biotech News

Immunovia has announced new performance data for PancreaSure in support of its upcoming Medicare coverage application.

SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.

Evaxion announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.

Pharmability has announced the submission of a Clinical Trial Application (CTA) for TIR-C, the company’s lead drug candidate for atopic dermatitis (eczema).

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

Oncopeptides’ clinical trial application for the “Window-of-Opportunity” (WoO) study in glioblastoma has been formally approved in Norway.

Orexo has announced positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology.

AnaCardio has announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).

The independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has been met and recommends that an additional two patients are enrolled at the dose level of 15 MBq/kg to provide a basis for defining a recommended phase II dose and completion of the phase I part of the study.

Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).